相关实验视频
Updated: Jul 29, 2026

14:04
Viral Nanoparticles for In vivo Tumor Imaging
Published on: November 16, 2012
17.3K
选择性器官向纳米颗粒:从设计到临床翻译
1CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, China. wanghai@nanoctr.cn.
Nanoscale horizons
|July 10, 2023
概括
准纳米粒子提供了精确的疾病治疗,但它们在人体中的命运仍然不清楚. 本综述探讨了纳米粒子生物分布和器官特定向策略,以改善药物输送.
科学领域:
- 纳米医学是一种纳米医学.
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 向纳米颗粒是一种有前途的治疗策略,用于精确治疗疾病.
- 纳米级药物递送系统的进步提高了针对纳米颗粒的潜力.
- 针对特定器官的纳米颗粒的一个关键挑战是了解它们的体内命运.
研究的目的:
- 审查纳米颗粒的体内旅程,包括生物障碍和准策略.
- 根据最近的文献来说明选择性器官向纳米颗粒的设计.
- 通过临床试验和市场药物数据,讨论针对器官的纳米颗粒的前景和挑战.
主要方法:
- 对纳米粒子体内行为和准策略的文献综述.
- 对各种器官的选择性准纳米粒子设计的分析.
- 临床试验和市场药物数据的汇编,用于前景和挑战评估.
主要成果:
- 描述了纳米粒子在体内的旅程,生物障碍和器官向策略.
- 选择性器官向纳米颗粒的设计策略用文献示例来说明.
- 临床数据提供了有关当前针对器官的纳米粒子前景和挑战的见解.
结论:
- 了解纳米粒子体内命运对于开发有效的器官向策略至关重要.
- 该审查为设计有选择性器官向纳米颗粒提供了一个参考.
- 需要进一步的研究和临床验证来克服挑战,并充分发挥针对器官的纳米颗粒的潜力.
相关概念视频
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

